Cancer Services at NSLHD Neuroendocrine Tumour Treatments NSLHD is a leading provider of cancer treatments and support for patients. Exemplary multidisciplinary research feeds into the highest quality, evidence-based clinical care, leading to excellent outcomes for our patients and the broader community. NSLHD hosts the NSWHealth funded Centre of Excellence for Neuroendocrine Tumour (NETs) Treatments. The Centre uses an advanced radiation therapy known as a “theranostics”, which combines diagnostic imaging and therapy using the same molecular approach. This approach has been driven by translational research within Sydney Vital, the Cancer Institute NSW funded research centre based at NSLHD. In recognition of the high quality of patient management, with treatment strategies defined by research output, the Centre has been formally designated as an “ENETS Centre of Excellence”, of which there are only four outside of Europe, by the European Neuro-Endocrine Tumour Society (ENETS). Further recognition of the talent and research output from the group was the success of a Five Year NHMRC Investigator Award of over $600,000 to Dr David Chan, a former research fellow of the Sydney Vital NETs program. Dr Chan has been funded to further develop prognostic imaging biomarkers for improving the outcomes in NETs patients.
Sydney Vital Sydney Vital is a Translational Cancer Research Centre based at NSLHD that aims to ensure the latest advances in cancer prevention, treatments and care are available to patients in the shortest time possible. The group also coordinates research facilities that facilitate the translating of cancer research from the laboratories into routine patient care and improve treatment guidelines. As an example of this work, treatment and care for people with cancer involves a number of different medical and health care professionals. Evidence suggests that centres that take a team approach to cancer care, in which health care professionals as a group consider treatment options and develop individualised treatment plans for each patient, can reduce mortality and improve quality of life for the patient. Multi-Disciplinary Team (MDT) meetings are thus an ideal vehicle to converge expertise across all relevant medical and health care professionals, along the integral patient pathway, to facilitate improved patient outcomes by incorporating treatment feedback loops. At NSLHD, MDTs are used in conjunction with randomised controlled trials (RCTs) as the mainstay of new treatment assessment to ensure the best outcomes for our patients, and the broader community.
The Cancer and Palliative Care Network hosts a significant amount of research in advanced practices and devices to improve radiotherapy patient outcomes across NSLHD. NSLHD was the first centre in Australia to provide adaptive radiation therapy using the Varian Ethos System. This pathway improves patient outcomes by customising treatment on a daily basis to reflect changes to patient anatomy.
9
Made with FlippingBook - professional solution for displaying marketing and sales documents online